HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Acquired Immune Deficiency Syndromes

• Publication date

  2004-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00126334-200408150-00016PMID 15247566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.

  2003cited by this paper
• Drug resistance mutations in HIV-1.

  2003cited by this paper
• Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.

  2003cited by this paper
• Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.

  2003cited by this paper
• Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.

  2002cited by this paper
• Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance

  2002cited by this paper
• World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing

  2001cited by this paper

• An in‐house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV‐1

  2012cites this paper
• The role of the HIV-1 reverse transcriptase mutation H208Y to drug resistance and viral fitness

  2011cites this paper
• The “Connection” Between HIV Drug Resistance and RNase H

  2010cites this paper
• Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.

  2008cites this paper
• Antiretroviral (ARV) drug resistance in the developing world.

  2007cites this paper
• Novel drug resistance mutations in HIV: recognition and clinical relevance.

  2006cites this paper
• Impact of unreported HIV‐1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non‐nucleoside inhibitors

  2006cites this paper